세계의 항생제 내성 시장 : 질병 유형별, 병원체 유형별, 약물 유형별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2023-2030년)

Antibiotic Resistance Market, By Disease Type, By Pathogen Type, By Drug Class, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,502,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,441,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,826,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항생제 내성 시장 규모는 2022년 80억 570만 달러로 평가되었고, 2023년부터 2023년까지 연평균 6.1%의 성장률을 나타낼 것으로 예상됩니다.

항생제 내성 시장 - 시장 역학

• 세균성 감염증의 유병률 증가로 시장 성장 확대.
• 기존 항생제에 내성을 가진 세균성 질환의 확산은 새로운 치료제에 대한 수요를 증가시켜 시장 성장을 가속할 수 있습니다. 항생제 내성이 확산됨에 따라 새로운 항생제의 필요성이 더욱 절실해집니다. 이는 제약사들의 연구개발에 대한 투자를 증가시킬 수 있습니다. 세균 감염에 대한 세계 종합적인 추정치가 발표되었는데, 2019년에 세계적으로 770만 명이 세균 감염으로 인해 사망한 것으로 나타났습니다. 이는 세계 사망자 8명 중 1명에 해당합니다. 약물 연구에 AI와 머신러닝을 통합하는 것은 새로운 항생제 창출을 가속화할 수 있는 성장 기회가 될 것입니다. 그러나 항생제 내성은 일반인이나 의료진에게조차 널리 인식되지 않고 있습니다. 이는 잘못된 처방과 오남용으로 이어질 수 있습니다.

항생제 내성 시장 - 세분화 분석

• 세계 항생제 내성 시장은 질병 유형, 병원체 유형, 약물 유형, 최종 사용자 및 지역별로 세분화되어 있습니다.
• 시장은 질병 유형에 따라 요로 감염, 복강 내 감염, 혈류 감염, 클로스트리듐 디피실 감염 및 기타 4 가지 범주로 나뉩니다. 요로 감염이 시장 성장을 주도하고 있습니다. 요로 결석은 인간, 특히 여성이 앓고 있는 가장 흔한 세균성 질환 중 하나입니다. 요로 결석은 종종 항생제로 치료됩니다. 그러나 항생제 내성이 확산됨에 따라 요로결석의 관리와 치료가 더욱 어려워지고 있습니다.
• 시장은 병원체 유형에 따라 아시네토박터 바우마니, 녹농균, 황색포도상구균, 폐렴구균, 기타 4가지 범주로 나뉩니다. 아시네토박터 바우마니가 시장 성장을 주도하고 있습니다. 아시네토박터 바우마니는 내성 메커니즘을 빠르게 획득하는 고유한 경향이 있어 병원 환경, 특히 중환자실(ICU)에서 가장 골치 아픈 감염 중 하나입니다.
• 시장은 약물 유형에 따라 옥사졸리디논 계열, 리포글리코펩타이드 계열, 테트라사이클린 계열 및 기타 세 가지 범주로 분류됩니다. 옥사졸리디논 계열이 시장을 지배하고 있으며, 예측 기간 동안에도 그 우위를 유지할 것으로 보입니다. 옥사졸리디논 계열은 세균 감염, 특히 그람 양성 병원균에 의한 감염을 치료하는 데 사용되는 항생제입니다. 옥사졸리디논 계열은 리네졸리드(Linezolid)가 가장 유명합니다. 메티실린 내성 황색포도상구균(MRSA), 반코마이신 내성 장구균(VRE) 등 다제내성 병원균에도 효과가 있는 것으로 나타나 특히 중요한 약물입니다.
• 시장은 최종 사용자에 따라 병원, 재택의료, 전문 클리닉, 기타로 분류됩니다. 시장을 독점하고 있는 것은 병원 부문입니다. 병원은 항생제 내성 개발에 필수적입니다. 병원은 내성균의 온상인 동시에 이러한 슈퍼박테리아에 감염된 사람들을 치료하는 주요 전장이기도 합니다. 병원이 항생제 내성 발생에 직면하는 의미는 복잡하고 의료 시장에 큰 영향을 미칩니다.

항생제 내성 시장 - 지리적 통찰력

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다. 북미는 전염병 전염병과 의료 지출 증가로 인해 시장 성장을 주도할 것으로 예상됩니다. 북미, 특히 미국에서는 항생제 내성이 있는 많은 감염성 질환이 발생하고 있습니다. 예를 들어, MRSA(메티실린 내성 황색포도상구균)는 미국의 많은 병원과 의료 현장에서 큰 문제가 되고 있습니다. 미국은 세계 어느 나라보다 국민 1인당 의료비 지출이 많은 나라다. 미국 의사협회에 따르면, 그 수입의 대부분은 연구, 의약품 개발 및 진단에 사용됩니다. 미국의 의료비는 2021년 2.7% 증가한 4조 3,000억 달러, 국민 1인당 1만 2,914달러를 지출할 것으로 예상됩니다. 이 성장률은 2020년(10.3%)보다 훨씬 낮습니다. 유럽과 아시아태평양은 효과적인 항생제 치료에 대한 수요가 증가함에 따라 이중특이성 내성 시장 수요가 증가할 것으로 예상됩니다.

항생제 내성 시장 - 경쟁 구도

항생제 내성이 세계 주요 문제로 떠오르고 있습니다. 박테리아가 진화하여 기존 약물에 내성을 갖게 되면 감염 치료가 더 어려워지고 질병이 길어지고 입원이 증가하며 사망률이 높아집니다. 각 제약회사들은 항생제 연구에 적극적이었으나 경제적 압박으로 인해 일부 대형 제약회사들은 항생제 연구 프로젝트를 축소하거나 중단하고 있으며, Pfizer, Merck, GlaxoSmithKline, Roche는 제약업계에 종사하는 대표적인 기업입니다. 종합적인 경쟁 조사는 제약 회사, 진단 회사, 연구 기관, 대체 치료법을 고려해야 합니다. 예를 들어, 2021년 5월 Basilea Pharmaceutical Ltd.(SIX: BSLN)는 약제 내성 감염의 진단, 예방 및 치료를 위한 항균 제품의 조기 개발을 지원하는 세계 파트너십인 CARB-X(Combating Antibiotic- Resistant Bacteria Biopharmaceutical Accelerator)로부터 최대 270만 달러의 보조금을 받았다고 밝혔습니다.

목차

제1장 항생제 내성 시장 개요

• 조사 범위
• 시장 추정 연도

제2장 주요 요약

• 시장 내역
• 경쟁 인사이트

제3장 항생제 내성 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 항생제 내성 산업 조사

• PEST 분석
• Porter의 Five Forces 분석
• 성장 전망 매핑
• 규제 구조 분석

제5장 항생제 내성 시장 : COVID-19의 영향 분석

• 신형 코로나바이러스 이전의 영향 분석
• 신형 코로나바이러스 이후의 영향 분석

제6장 항생제 내성 시장 구도

• 항생제 내성 시장 점유율 분석, 2022년
• 주요 제조업체별 분석 데이터
  • 기존 기업 분석
  • 신규 기업 분석

제7장 항생제 내성 시장 - 질환 유형별

• 개요
  • 질환 유형별 부문 점유율 분석
  • 요로 감염
  • 복강내 감염증
  • 혈류감염
  • 클로스트리듐 디피실리균 감염증
  • 기타

제8장 항생제 내성 시장 - 병원체 유형별

• 개요
  • 병원체 유형별 부문 점유율 분석
  • 아시네토박터 바우만 니
  • 녹농균
  • 황색포도상 구균
  • 폐렴 연쇄구균
  • 기타

제9장 항생제 내성 시장 - 약제 클래스별

• 개요
  • 약제 클래스별 부문 점유율 분석
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • 기타

제10장 항생제 내성 시장 - 최종사용자별

• 개요
  • 최종사용자별 부문 점유율 분석
  • 병원
  • 홈케어
  • 전문 클리닉
  • 기타

제11장 항생제 내성 시장 - 지역별

• 서론
• 북미
  • 개요
  • 북미 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양
  • 개요
  • 아시아태평양 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제12장 주요 벤더 분석 - 항생제 내성 산업

• 경쟁 대시보드
• 기업 개요
  • Achaogen Inc
  • Nabriva Therapeutics plc
  • BioVersys AG
  • Johnson &Johnson Services, Inc.
  • Destiny Pharma plc
  • Armata Pharmaceuticals, Inc.
  • West Way Health
  • The Medicines Company
  • Merck &Co., Inc.
  • Pfizer Inc.
  • CARB-X
  • Melinta Therapeutics LLC
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • GSK plc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd

제13장 애널리스트 전방위 전망

LSH

영문 목차

영문목차

REPORT HIGHLIGHT

Antibiotic Resistance Market size was valued at USD 8,005.7 million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.

Antibiotic resistance emerges when bacteria adapt to the usage of these medications. It develops in bacteria instead of people or animals. These bacteria can infect humans and animals, and their infections are more difficult to treat than infections caused by non-resistant bacteria. Antibiotic resistance is accelerated by antibiotic abuse and overuse, as well as inadequate infection prevention and control. At all levels of society, steps can be made to decrease the impact and spread of resistance. Antibiotic resistance is a global issue and requires cooperation between nations, industries, and organizations. Investing in the development of new antibiotics, as well as alternative therapies like bacteriophages and antimicrobial peptides. For example, Methicillin-Resistant Staphylococcus Aureus (MRSA's) emergence and spread show the quick rate at which germs can adapt to drugs, as well as the continual problem that healthcare personnel face in treating bacterial illnesses. It emphasizes the critical need for effective antibiotic usage, improved infection control procedures, and the discovery of novel antibiotics.

Antibiotic Resistance Market - Market Dynamics:

• Increasing the prevalence of bacterial infection to increase market growth

• The increasing prevalence of bacterial illnesses resistant to conventional antibiotics may increase demand for novel remedies, driving market growth. As antibiotic resistance spreads, the need for new antibiotics becomes more pressing. This could lead to increased investment in R&D by pharmaceutical corporations. Global comprehensive estimates of the burden of bacterial infections have been published. In 2019, 7.7 million deaths around the world were found to be linked to bacterial infections. That equals 1 in 8 of all global deaths. The integration of AI and machine learning in drug research provides a growth opportunity to accelerate the creation of novel antibiotics. However, Antibiotic resistance is not widely recognized by the general population and even by healthcare providers. This can lead to incorrect prescribing and abuse.

Antibiotic Resistance Market - Key Insights:

• As per the analysis shared by our research analyst, the global Antibiotic Resistance market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)

• Based on Disease type segmentation, Urinary Tract Infections was predicted to show maximum market share in the year 2022

• Based on Pathogen Type segmentation, Acinetobacter Baumannii was the leading type in 2022

• Based on Drug class segmentation, Oxazolidinones were the leading type in 2022

• Based on End-User segmentation, Hospitals was the leading type in 2022

• On the basis of region, North America was the leading revenue generator in 2022

Antibiotic Resistance Market- Segmentation Analysis:

• The Global Antibiotic Resistance Market is segmented on the basis of Disease type, Pathogen Type, Drug class, End-User, and Region.

• The market is divided into four categories based on Disease type: Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, and Others. Urinary Tract Infections dominate the market growth. UTIs are one of the most common bacterial diseases that affect humans, particularly women. UTIs are often treated with antibiotics. However, with the increasing prevalence of antibiotic resistance, managing and treating UTIs is becoming more difficult.

• The market is divided into four categories based on Pathogen Type: Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus pneumonia, and Others. Acinetobacter Baumannii dominates the market growth. A. baumannii has an inherent propensity to rapidly acquire resistance mechanisms, making it one of the most troublesome infections in hospital settings, particularly in intensive care units (ICUs).

• The market is divided into three categories based on Drug class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others. The Oxazolidinones sector dominates the market and is likely to maintain its dominance during the forecast period. Oxazolidinones are antibiotics that are used to treat bacterial infections, particularly those caused by Gram-positive pathogens. Linezolid is the most well-known oxazolidinone. They are especially significant since they have been shown to be effective against multi-drug resistance pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

• The market is divided into three categories based on End-User: Hospitals, Homecare, Specialty Clinics, and Others. The hospital sector dominates the market. Hospitals are essential to the development of antibiotic resistance. They are both a breeding ground for resistant bacteria and a main battleground for treating people sick with these superbugs. The implications for hospitals in the face of developing antibiotic resistance are complex, with considerable ramifications for the healthcare market.

Antibiotic Resistance Market - Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market, due to the increasing prevalence of infectious diseases and rising healthcare expenditure. North America, especially the United States, has had outbreaks of many infectious diseases, some of which are antibiotic-resistant. MRSA (Methicillin-resistant Staphylococcus aureus), for example, has become a major concern in many U.S. hospitals and healthcare settings. The United States spends more on healthcare per capita than any other country in the world. According to the American Medical Association, a significant amount of the revenue is spent on research, drug development, and diagnostics. Health spending in the U.S. increased by 2.7% in 2021 to USD 4.3 trillion or USD 12,914 per capita. This growth rate is substantially lower than in 2020 (10.3% percent). Europe and Asia Pacific are projected to demand for Bispecific Resistance Market, due to the growing demand for effective antibiotic therapies.

Antibiotic Resistance Market- Competitive Landscape:

Antibiotic resistance has emerged as a major global concern. As bacteria evolve and become resistant to existing medicines, infections become more challenging to treat, leading to longer illnesses, more hospitalizations, and a rise in mortality. The manufacturers have been active in antibiotic research, however owing to economic pressures, some large pharmaceutical corporations have reduced or discontinued their antibiotic research projects. Pfizer, Merck, GlaxoSmithKline, and Roche represent some of the companies involved in the pharmaceutical industry. A comprehensive competitive study must consider pharmaceutical businesses, diagnostic companies, research institutes, and alternative treatment modalities. For instance, On May 2021, Basilea Pharmaceutical Ltd. (SIX: BSLN) announced today that it has been awarded a grant of up to USD 2.7 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership dedicated to supporting the early development of antibacterial products to diagnose, prevent and treat drug-resistant infections.

Recent Developments:

November 18, 2020, Merck, known as MSD outside the United States and Canada, recently, announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world's largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIBIOTIC RESISTANCE MARKET KEY PLAYERS

• Achaogen Inc
• Nabriva Therapeutics plc
• BioVersys AG
• Johnson & Johnson Services, Inc.
• Destiny Pharma plc
• Armata Pharmaceuticals, Inc.
• West Way Health
• The Medicines Company
• Merck & Co., Inc.
• Pfizer Inc.
• CARB-X
• Melinta Therapeutics LLC
• Novartis AG
• Vertex Pharmaceuticals Incorporated
• GSK plc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE TYPE

• Urinary Tract Infection
• Intra-Abdominal Infections
• Blood Stream Infections
• Clostridium Difficile Infections
• Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN TYPE

• Acinetobacter Baumannii
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• Streptococcus pneumoniae
• Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS

• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END-USER

• Hospitals
• Homecare
• Specialty Clinics
• Others

GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Antibiotic Resistance Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Antibiotic Resistance Market Snippet by Disease Type
  • 2.1.2. Antibiotic Resistance Market Snippet by Pathogen Type
  • 2.1.3. Antibiotic Resistance Market Snippet by Drug Class
  • 2.1.4. Antibiotic Resistance Market Snippet by End-User
  • 2.1.5. Antibiotic Resistance Market Snippet by Country
  • 2.1.6. Antibiotic Resistance Market Snippet by Region
• 2.2. Competitive Insights

3. Antibiotic Resistance Key Market Trends

• 3.1. Antibiotic Resistance Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Antibiotic Resistance Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Antibiotic Resistance Market Opportunities
• 3.4. Antibiotic Resistance Market Future Trends

4. Antibiotic Resistance Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Antibiotic Resistance Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Antibiotic Resistance Market Landscape

• 6.1. Antibiotic Resistance Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Antibiotic Resistance Market - By Disease Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease Type, 2022 & 2030 (%)
  • 7.1.2. Urinary Tract Infection
  • 7.1.3. Intra-Abdominal Infections
  • 7.1.4. Blood Stream Infections
  • 7.1.5. Clostridium Difficile Infections
  • 7.1.6. Others

8. Antibiotic Resistance Market - By Pathogen Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Pathogen Type, 2022 & 2030 (%)
  • 8.1.2. Acinetobacter Baumannii
  • 8.1.3. Pseudomonas Aeruginosa
  • 8.1.4. Staphylococcus Aureus
  • 8.1.5. Streptococcus pneumoniae
  • 8.1.6. Others

9. Antibiotic Resistance Market - By Drug Class

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
  • 9.1.2. Oxazolidinones
  • 9.1.3. Lipoglycopeptides
  • 9.1.4. Tetracyclines
  • 9.1.5. Others

10. Antibiotic Resistance Market - By End-User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End-User, 2022 & 2030 (%)
  • 10.1.2. Hospitals
  • 10.1.3. Homecare
  • 10.1.4. Specialty Clinics
  • 10.1.5. Others

11. Antibiotic Resistance Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Antibiotic Resistance Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Antibiotic Resistance Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.9. Italy
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.9.3. Italy Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.9.4. Italy Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.10. United Kingdom
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.10.3. United Kingdom Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.10.4. United Kingdom Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.11. France
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.11.3. France Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.11.4. France Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.11.5. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.11.6. France Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.12. Russia
    • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.12.2. Russia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.12.3. Russia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.13. Netherlands
    • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.13.2. Netherlands Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.13.3. Netherlands Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.14.2. Sweden Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.15. Poland
    • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.15.2. Poland Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.15.3. Poland Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.3.16. Rest of Europe
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Antibiotic Resistance Key Manufacturers in Asia Pacific
  • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
  • 11.4.5. Asia Pacific Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
  • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.8. India
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.8.3. India Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.8.4. India Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.8.5. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.8.6. India Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.9. China
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.9.3. China Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.9.4. China Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.9.5. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.9.6. China Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.13. Thailand
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.13.3. Thailand Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.13.4. Thailand Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.14. Indonesia
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.14.3. Indonesia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.4.16. Rest of APAC
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.4.16.3. Rest of APAC Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.4.16.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
• 11.5. Latin America
  • 11.5.1. Overview
  • 11.5.2. Antibiotic Resistance Key Manufacturers in Latin America
  • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.5.4. Latin America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
  • 11.5.5. Latin America Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
  • 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 11.5.7. Latin America Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
• 11.6. Middle East and Africa
  • 11.6.1. Overview
  • 11.6.2. Antibiotic Resistance Key Manufacturers in Middle East and Africa
  • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 11.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
  • 11.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
  • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)
  • 11.6.14. Rest of MEA
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 11.6.14.3. Rest of MEA Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 11.6.14.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2018 - 2030 (US$ Million)
    • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Antibiotic Resistance Industry

• 12.1. Competitive Dashboard
• 12.2. Company Profiles
  • 12.2.1. Achaogen Inc
  • 12.2.2. Nabriva Therapeutics plc
  • 12.2.3. BioVersys AG
  • 12.2.4. Johnson & Johnson Services, Inc.
  • 12.2.5. Destiny Pharma plc
  • 12.2.6. Armata Pharmaceuticals, Inc.
  • 12.2.7. West Way Health
  • 12.2.8. The Medicines Company
  • 12.2.9. Merck & Co., Inc.
  • 12.2.10. Pfizer Inc.
  • 12.2.11. CARB-X
  • 12.2.12. Melinta Therapeutics LLC
  • 12.2.13. Novartis AG
  • 12.2.14. Vertex Pharmaceuticals Incorporated
  • 12.2.15. GSK plc.
  • 12.2.16. AbbVie Inc.
  • 12.2.17. F. Hoffmann-La Roche Ltd

13. 360 Degree Analyst View

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us

관련자료